Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Br J Pharmacol ; 134(1): 108-15, 2001 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-11522602

RESUMO

1. The contribution of sensory neurons and mast cells to the oedema evoked by adenosine A1 (N(6)-cyclopentyladenosine, CPA, 3 - 30 nmol site(-1)), A2 (5'N-ethylcarboxamidoadenosine, NECA, 1 - 10 nmol site(-1)) and A3 receptor agonists (N6-[3-iodobenzyl]-N-methyl-5'-carboxiamidoadenosine, IB-MECA, 0.01 - 3 nmol site(-1)) was investigated in the rat skin microvasculature, by the extravascular accumulation of intravenously-injected (i.v.) 125I-albumin. 2. Intradermal (i.d.) injection of adenosine and analogues induced increased microvascular permeability in a dose-dependent manner (IB-MECA > NECA > CPA > adenosine). The non-selective adenosine receptor antagonist theophylline (5 - 50 nmol site(-1)) markedly inhibited adenosine, CPA or NECA but not IB-MECA-induced plasma extravasation. The A1 receptor antagonist 1,3-dipropyl-8-cyclopentylxanthine (DPCPX, 0.3 - 3 micromol kg(-1), i.v.) significantly reduced CPA-induced plasma extravasation whereas responses to adenosine, NECA or IB-MECA were unchanged. The A2 receptor antagonist 3,7-dymethyl-1-proprargylxanthine (DMPX, 0.5 - 50 nmol site(-1)) significantly reduced NECA-induced plasma extravasation without affecting responses to adenosine, CPA and IB-MECA. 3. The tachykinin NK1 receptor antagonist (S)-1-[2-[3-(3,4-dichlorphenyl)-1 (3-isopropoxyphenylacetyl) piperidin-3-yl] ethyl]-4-phenyl-1 azaniabicyclo [2.2.2]octane chloride (SR140333), but not the NK2 receptor antagonist (S)-N-methyl-N[4-acetylamino-4-phenyl piperidino)-2-(3,4-dichlorophenyl)butyl]-benzamide (SR48968), significantly inhibited the plasma extravasation evoked by higher doses of adenosine (100 nmol site(-1)), CPA (100 nmol site(-1)), NECA (1 nmol site(-1)) and IB-MECA (0.1 - 1 nmol site(-1)). In rats treated with capsaicin to destroy sensory neurons, the response to higher doses of adenosine, CPA and NECA, but not IB-MECA, was significantly inhibited. 4. The effects of adenosine and analogues were largely inhibited by histamine and 5-hydroxytryptamine (5-HT) antagonists and by compound 48/80 pretreatment. 5. In conclusion, our results provide evidence that adenosine A1 and A2, but not A3, receptor agonists may function as cutaneous neurogenic pro-inflammatory mediators; acting via microvascular permeability-increasing mechanisms that can, depending on dose of agonist and purine receptor under study, involve the tachykinin NK1 receptor and mast cell amines.


Assuntos
Adenosina/análogos & derivados , Adenosina/farmacologia , Proteínas Sanguíneas/efeitos dos fármacos , Permeabilidade Capilar/efeitos dos fármacos , Pele/efeitos dos fármacos , Adenosina-5'-(N-etilcarboxamida)/farmacologia , Animais , Proteínas Sanguíneas/metabolismo , Capsaicina/farmacologia , Relação Dose-Resposta a Droga , Feminino , Injeções Intradérmicas , Soluções Isotônicas/farmacologia , Masculino , Mastócitos/efeitos dos fármacos , Mastócitos/fisiologia , Antagonistas dos Receptores de Neurocinina-1 , Neurônios Aferentes/efeitos dos fármacos , Fragmentos de Peptídeos/farmacologia , Piperidinas/farmacologia , Agonistas do Receptor Purinérgico P1 , Antagonistas de Receptores Purinérgicos P1 , Quinuclidinas/farmacologia , Ratos , Ratos Wistar , Receptores da Neurocinina-2/antagonistas & inibidores , Pele/irrigação sanguínea , Pele/metabolismo , Substância P/análogos & derivados , Substância P/farmacologia , Teobromina/análogos & derivados , Teobromina/farmacologia , p-Metoxi-N-metilfenetilamina/farmacologia
2.
Life Sci ; 69(13): 1573-85, 2001 Aug 17.
Artigo em Inglês | MEDLINE | ID: mdl-11554618

RESUMO

Capsaicin, the pungent component of hot peppers, and the venom of the spider Phoneutria nigriventer are able to activate sensory nerves resulting in cutaneous neurogenic plasma extravasation. This study was undertaken to compare the ability of these substances to evoke oedema in the rat hind-paw and mechanisms underlying this effect. Subplantar injection of either Phoneutria nigriventer venom (PNV; 1-100 microg/paw) or capsaicin (10-200 microg/paw) caused a significant paw oedema that was potentiated by CGRP (10 pmol/paw). In rats treated neonatally with capsaicin to deplete neuropeptides, the paw oedema induced by either PNV (100 microg/paw) or capsaicin (100 microg/paw) was partially reduced (P<0.05). The tachykinin NK1 receptor antagonist SR140333 (0.2 micromol/kg; i.v.) prevented the paw oedema induced by the tachykinin NK1 receptor agonist GR73632 (30 pmol/paw) and partially reduced paw oedema induced by PNV or capsaicin. Treatment of rats with compound 48/80 (5 mg/kg; s.c. 3 days) or with both H1 receptor antagonist (mepyramine; 1 nmol/paw) and 5-HT receptor antagonist (methysergide; 1 nmol/paw) significantly inhibited PNV- or capsaicin-induced paw oedema. The combined treatment with mepyramine and methysergide and SR140333 further reduced PNV- and capsaicin-induced paw oedema. The bradykinin B2 receptor antagonist Hoe 140 affected neither PNV- nor capsaicin-induced responses. Our results suggest that PNV and capsaicin each induce paw oedema that is partially mediated by activation of sensory fibers culminating in the release of substance P as well as by activation of mast cells which in turn release amines such as histamine and 5-HT.


Assuntos
Capsaicina/toxicidade , Edema/induzido quimicamente , Venenos de Aranha/toxicidade , Animais , Animais Recém-Nascidos , Peptídeo Relacionado com Gene de Calcitonina/farmacologia , Permeabilidade Capilar/efeitos dos fármacos , Edema/patologia , Feminino , Pé/inervação , Pé/patologia , Antagonistas dos Receptores Histamínicos H1/farmacologia , Indicadores e Reagentes , Masculino , Mastócitos/efeitos dos fármacos , Mastócitos/fisiologia , Antagonistas dos Receptores de Neurocinina-1 , Neurônios Aferentes/efeitos dos fármacos , Piperidinas/farmacologia , Quinuclidinas/farmacologia , Ratos , Ratos Wistar , p-Metoxi-N-metilfenetilamina/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA